Austria suspends AstraZeneca COVID-19 vaccine group after death

Austrian authorities suspended the vaccinations with a group of AstraZeneca’s COVID-19 vaccine as a precaution while investigating the deaths of one person and the disease of another after the shots, a health agency said on Sunday. ‘BASG) received two reports in a temporary connection with the vaccination of the same AstraZeneca vaccine in the district clinic of Zwettl in the province of Lower Austria. One 49-year-old woman has died as a result of severe clotting. diseases, while a 35-year-old woman has developed a pulmonary embolism and is recovering, it is said. A pulmonary embolism is an acute lung disease caused by a ruptured blood clot. “There is currently no evidence of a causal link with the vaccination,” BASG said. women were both nurses who worked at the Zwettl clinic. According to BASG, blood clotting is not one of the known side effects of the vaccine. The company followed its investigation vigorously to eliminate any possible link altogether. “As a precaution, the remaining stock of the vaccine in question will no longer be issued or vaccinated,” he added.

A spokesman for AstraZeneca said, “There were no confirmed serious side effects associated with the vaccine,” adding that all groups were subject to strict and strict quality control. Trials and actual experience so far indicate that the vaccine is safe and effective, and it has been approved for use in more than 50 countries, he said. AstraZeneca also said it was in contact with the Austrian authorities and would fully support the investigation. At the end of January, European Union regulators approved the product, saying it was effective and safe. while the World Health Organization (WHO) listed the product for emergency use in mid-February. Trials seen in trials were mostly of short duration and problems with blood clotting were not reported. A safety assessment by the German vaccine regulator of more than 360,000 people who received the AstraZeneca vaccine in the country between the launch in early February and February 26, concluded that the side has the safety profile described in clinical trials.